Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy

Diabetic Nephropathy Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01673204
• Other study ID #: SNUH-TNFR
• Status: Recruiting
• Phase: Phase 4
• First received: August 21, 2012
• Last updated: February 12, 2014
• Start date: October 2012

Study information

• Verified date: February 2014
• Source: Seoul National University Hospital
• Contact: Sumi Lee
• Phone: 82-2-2072-1724
• Email: promise131[@]hanmail.net
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Worldwide, the most common cause of chronic kidney disease (CKD) and end stage renal disease (ESRD) is diabetes. Unlike the past, in south korea, diabetes account for more than 40% of ESRD. According to WHO reports in 1998, 100 million people had type 2 diabetes in 1997, and there is expected to increase by 300 million people in 2025. In addition, the expected survival time of patients with diabetes increase compared to previous. In the future, ESRD due to type 2 diabetes is expected to have a significant impact on the health industry. Therefore, prevention of progression to CKD and ESRD in diabetic patients is important to aspect of national health and economic problems. How to stop the progression of diabetic nephropathy is part of modern medicine to be solved.

Strict glycemic control, blood pressure regulation, and use of renin-angiotensin system (RAS) blockers inhibit the development and progression of diabetic nephropathy. Microalbuminuria in diabetic patients has been recognized as a predictor of progression of diabetic nephropathy. Thus, the prevention of elevated urinary albumin excretion is an important therapeutic target for the prevention of renal and cardiovascular events.

In patients with diabetes and hypertension, the drugs that block the RAS are used to treat proteinuria, but still a large number of patients with proteinuria are uncontrolled. In addition, ACE inhibitors or ARB agents actually have a limited effect on reducing the risk of cardiovascular or renal outcome. Also, sulodexide or pentoxyphylline which is reducing proteinuria have some weak evidence in terms of efficacy and safety. Therefore, the introduction of new alternative drugs are required.

Already several study reported that calcitriol or paricalcitol in the renal injury model have renopreventive effect. In addition, in diabetic renal injury mice model reported that vitamin D receptor deficiency leads to glomerulosclerosis. Inhibition of the RAS with combination of paricalcitol and RAS inhibitors effectively prevent renal injury in diabetic nephropathy. Recently, Dick de Zeeuw et al reported that addition of paricalcitol to RAS inhibition safely lower residual albuminuria in patients with diabetic nephropathy. Recent studies reported that elevated concentrations of serum markers of the TNFα and Fas-pathways are strongly associated with decreased renal function in diabetic patients. However, the role of these markers in early progressive renal function decline are not clear. Therefore, the objective of this study is to identify the renoprotective effect as an new treatment of activated vitamin D (Calcitriol) indicating the TNF-α-related anti-inflammatory action and to seek the role as an important biomarker that the changes of TNFR in diabetic nephropathy can predict response to treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 276
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years to 80 Years

Eligibility

Inclusion Criteria:

• patients age 19-80 years

• Clinically proven diabetic nephropathy

• MDRD eGFR >= 30mL/min/1.73m2

• Patients with residual urine protein/creatinine ratio >= 200mg/g

• Adequate blood pressure control as treated systolic blood pressure <=140 or diastolic <=90 mmHg with RAS inhibitor for more than 3months

• Serum intact PTH <500 mg/dL

• Serum calcium <10.2 mg/dL

• Patients who have not been treated vitamin D within the 3months prior to signing the informed consent form

Exclusion Criteria:

• Patients age <19 years or > 80years

• Patients with rapidly progressive glomerulonephritis

• Patients requiring renal replacement therapy immediately

• Hypercalcemia(Uncorrected serum calcium level >10.2 mg/dL) within recent 3month

• Malignant hypertension

• Heart failure (New York Heart Association functional class II to IV or LVEF <40%)

• Severe chronic obstructive lung disease

• Decompensated liver disease (ALT >3X upper normal limit)

• Known allergy or hypersensitivity to vitamin D

• Current treatment with steroids and/or immunosuppressive agents

• Active primary malignancy requiring treatment or survival limits less than 2years

• History of noncompliance to medical regimen

• Inability to give an informed consent or to cooperate with researchers

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening

Related Conditions & MeSH terms

• Diabetic Nephropathies
• Diabetic Nephropathy
• Kidney Diseases

Intervention

Drug:
• Calcitriol
dosage of 0.5mcg administered orally once daily for 12 month
• Placebo

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University Boramae Medical Center	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in renal function with proteinuria	Comparison of in GFR level from baseline Comparison of proteinuria amount checked by random urine protein/creatinine ratio	12 month after administration	No
Secondary	changes in sTNFR and TNF-related proteins	Comparison of serum TNFR1, TNFR2 levels from baseline	12 months after administration	No